Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gyre Therapeutics (GYRE) Leases (2019 - 2025)

Gyre Therapeutics (GYRE) has disclosed Leases for 7 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Leases fell 37.79% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 37.79% year-over-year, with the annual reading at $1.1 million for FY2025, 37.79% down from the prior year.
  • Leases for Q4 2025 was $1.1 million at Gyre Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Leases was $3.1 million in Q2 2021, with the low at $17000.0 in Q1 2023.
  • Average Leases over 5 years is $1.5 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Leases crashed 99.24% in 2023, then surged 2011.76% in 2024.
  • Over 5 years, Leases stood at $2.7 million in 2021, then crashed by 75.73% to $666000.0 in 2022, then decreased by 26.58% to $489000.0 in 2023, then soared by 271.78% to $1.8 million in 2024, then crashed by 37.79% to $1.1 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $1.1 million, $1.8 million, and $2.0 million for Q4 2025, Q4 2024, and Q3 2024 respectively.